Role of Inflammation and Angiogenic Growth Factors in Malignant Mesothelioma by Albonici, Loredana et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 3 
 
 
 
 
© 2012 Albonici et al., licensee InTech. This is an open access chapter distributed under the terms of the 
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
Role of Inflammation and Angiogenic Growth 
Factors in Malignant Mesothelioma 
Loredana Albonici, Camilla Palumbo and Vittorio Manzari 
Additional information is available at the end of the chapter 
http://dx.doi.org/10.5772/47951 
1. Introduction 
Malignant mesothelioma (MM) is a highly aggressive tumor which arises from the 
mesothelial cell lining of the serosal surfaces, most cases (>90%) being of pleural origin 
(Attanoos & Gibbs, 1997; Robinson & Lake, 2005). The pathogenesis of MM has been mainly 
associated with previous asbestos exposure (Berman & Crump, 2008), with a latency period 
of up to 40 years, although other agents such as Simian virus 40 (SV40) or genetic 
susceptibility factors have been linked to the development of this tumor (Carbone et al., 
2002; Pisick & Salgia, 2005). Indeed, human mesothelial cells are highly susceptible to SV40-
mediated transformation in vitro and SV40 DNA sequences and large T antigen (Tag) have 
been detected in human MM cells (Bocchetta et al., 2000; Carbone et al., 2012; Gazdar et al., 
2003).  
MM is largely unresponsive to conventional chemotherapy or radiotherapy and, despite its 
low metastatic efficiency, it is highly invasive to surrounding tissues so that its extensive 
growth leads to the failure of the organs underlying the serosal membranes (Astoul, 1999). 
In fact, the primary cause of fatality in MM is related to the propensity of the tumor cells to 
invade locally, even though MM metastasis are more common after surgery and, at the 
autopsy, metastatic diffusion is observed in 50% of patients (Astoul, 1999). At present, the 
median survival from diagnosis of MM is less than two years (Palumbo et al., 2008). 
The mesothelium is not just a passive protective surface, but a highly dynamic membrane 
(Mutsaers, 2004). It consists of a single layer of elongated, flattened, squamous-like cells of 
mesodermal origin, characterized by dual epithelial/mesenchymal features. Cuboidal 
mesothelial cells can also be found at various locations in physiological conditions. Further, 
mesothelial cells can adopt a cuboidal morphology, which reflects a metabolically activated 
state, after injury or stimulation of the serosal surface (Mutsaers, 2004). Indeed, mesothelial 
cells are sentinel cells that can sense and respond to a variety of signals within their 
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microenvironment. They participate in serosal inflammation by secreting both pro- and anti-
inflammatory as well as immunomodulatory mediators. Besides, these cells can act as 
antigen presenting cells for T lymphocytes (Hausmann et al., 2000), regulate tissue repair, 
control fibrin deposition and breakdown, and modulate adhesion, growth and dissemination 
of tumor cells metastasizing to the serosal membranes (Mutsaers, 2002). In particular, in 
response to different types of stimuli, including cytokines and asbestos fibers, mesothelial cells 
have been reported to release prostaglandins, chemokines, reactive oxygen and nitrogen 
species and growth factors which represent key effectors in the modulation of inflammatory 
reactions that occur in response to pleural injury (Fleury-Feith et al., 2003; Mutsaers, 2002).  
2. Asbestos-induced carcinogenesis as an inflammation-driven process 
The association between exposure to asbestos fibers and development of lung cancer and 
mesothelioma is well established in both humans and animals models (Greillier & Astoul, 
2008; Huang et al., 2011; Mossman & Churg, 1998; Yarborough, 2007). A variety of 
mediators, either generated directly from asbestos fibers or elaborated intracellularly or 
extracellularly by cells exposed to asbestos, are implicated in the initiation and promotion of 
mesothelial cell transformation.  
The mechanisms underlying asbestos-induced carcinogenesis involve mutagenic and non-
mutagenic pathways, the latter including inflammation, enhanced mitogenesis, cell 
signaling alterations, and cytotoxic apoptosis/necrosis. Neither of these two mechanisms 
alone fully accounts for the complex biological abnormalities produced by asbestos fibers, 
even though in MM asbestos appears to act as a complete carcinogen (Dong et al., 1994; 
Huang et al., 2011). Still, the chronic inflammatory response induced by asbestos inhalation 
seems to play a critical role in mesothelial cell transformation.  
Asbestos exposure induces an inflammatory reaction with a large component of 
mononuclear phagocytes (Antony et al., 1993; Branchaud et al., 1993; Carbone et al., 2012; 
Choe et al., 1997). Upon differentiation into macrophages, these cells phagocytize asbestos 
fibers and, in response, release numerous cytokines and reactive oxygen species with 
mutagenic properties (Robledo & Mossman, 1999). Thus, many of the pathological 
consequences occurring in the lung following exposure to asbestos fibers are believed to arise 
from an inflammatory cascade involving both autocrine and paracrine events (Hillegass et al., 
2010). Persistent pulmonary inflammation is observed in animal models of asbestosis that can 
be correlated with fibroproliferative responses (Mossman & Churg, 1998).  
Experimental models, as well as in vitro studies, have shown that mesothelial cells are 
particularly susceptible to the cytotoxic effects of asbestos (Baldys et al., 2007; BéruBé et al., 
1996; Broaddus et al., 1996). Asbestos does not induce transformation of primary human 
mesothelial cells in vitro, instead, it is very cytotoxic to this cell type, causing extensive cell 
death. This finding raised an apparent paradoxical issue of how asbestos causes MM if 
human mesothelial cells exposed to this mineral die (Liu et al., 2000). This apparent paradox 
is reconciled by the current hypothesis that the chronic inflammation induced by asbestos 
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leads to the persistent activation of the nuclear factor kappa B (NF-κB) transcription factor, 
which in turn mediates the activation of prosurvival genes and prevents apoptosis of the 
damaged mesothelial cells (Mantovani et al., 2008; Micheau & Tschopp, 2003; Philip et al., 
2004). This allows mesothelial cells with asbestos-induced DNA damage to survive and 
divide rather than die and, if sufficient genetic damage accumulates, to eventually develop 
into a MM (Miura et al., 2006; Nymark, 2007). In fact, apoptosis is an important mechanism 
by which cells with DNA damage are eliminated without eliciting an inflammatory response 
(Ullrich et al., 2008; Yoshida et al., 2010). However, failure of apoptosis in cells with unrepaired 
DNA and chromosomal damage after chronic exposure to asbestos may lead to permanent 
genetic alterations and trigger the development of a clone of cancerous cells (Roos & Kaina, 
2006; Wu, 2006). Consistently, MM cells are found to be apoptosis-resistant as compared to 
primary cultured mesothelial cells (Fennel & Rudd, 2004; Villanova et al., 2008). 
2.1. Tumor Necrosis Factor-α and other pro-inflammatory cytokines 
Tumor Necrosis Factor-α (TNF-α) is probably the most studied candidate for initiating 
inflammatory and fibrotic events linked to lung diseases such as asbestosis. Asbestos fibers 
cause the accumulation of macrophages in the pleura and lung. When these macrophages 
encounter asbestos, they release TNF-α. At the same time, asbestos induces the secretion of 
TNF-α and the expression of TNF-α receptor I (TNF-RI) in mesothelial cells (Yang et al., 
2006). Remarkably, treatment of mesothelial cells with TNF-α significantly reduced asbestos 
cytotoxicity. Indeed, TNF-α activates NF-κB, which in turn promotes mesothelial cell survival 
and resistance to the cytotoxic effects of asbestos. Thus, TNF-α signaling through NF-κB-
dependent mechanisms increases the percentage of mesothelial cells that survive asbestos 
exposure, thereby increasing the pool of asbestos-damaged cells susceptible to malignant 
transformation (Haegens et al., 2007; Janssen-Heininger et al., 1999; Yang et al., 2006). 
It has been reported that rats receiving a single intratracheal instillation of fibrogenic 
chrysotile asbestos developed lung chronic inflammatory reactions characterized by the 
accumulation of alveolar macrophages producing elevated levels of both Interleukin (IL)-1 
and IL-6 (Lemaire & Ouellet, 1996). An increased production and/or release of these 
cytokines triggers inflammatory cell recruitment, thus amplifying and sustaining local 
inflammation. It has also been demonstrated that crocidolite asbestos and TNF-α can 
stimulate a dose-dependent increase in IL-6 expression and secretion from cultured, 
transformed and normal, human alveolar type II epithelial cells that is dependent upon 
intracellular redox potential (Simeonova et al., 1997). Interestingly, although MM cells appear 
to express low levels of IL-6 receptor (IL-6R), IL-6 can act as a growth factor for these cells 
through a trans-signaling mechanism involving the interaction of macromolecular complexes 
of IL-6 and soluble IL-6R (sIL-6R) with the transmembrane glycoprotein gp130 expressed on 
the surface of MM cells (Adachi et al., 2006; Rose-John et al., 2007). High levels of both IL-6 and 
sIL-6R are typical of several chronic inflammatory conditions (Rose-John et al., 2007). 
Thus, inflammatory cytokines such as TNF-α and IL-6 appear to play a dual role in MM 
pathogenesis: they induce and sustain pleural inflammation and at the same time can act as 
survival or mitogenic factors for normal and transformed mesothelial cells, respectively. 
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2.2. Reactive Oxygen and Nitrogen Species (ROS/RNS) 
The mechanisms of injury and disease development caused by asbestos fibers are presumed 
to be related to their greater fibrogenic and carcinogenic properties in comparison to other 
minerals. Asbestos–induced mutagenicity is mediated through both direct and indirect 
pathways. Asbestos fibers may induce mutagenicity and genotoxicity directly through 
physical interaction with the mitotic machinery after being phagocytized by the target cells, 
or indirectly as a result of DNA and chromosome damage caused by asbestos-induced 
reactive oxygen (ROS) and nitrogen species (RNS) (Kamp & Weitzman, 1999; Shukla et al., 
2003a, 2003b). ROS and RNS can be generated primarily by asbestos fibers or secondarily 
through fiber-induced inflammation (Aust et al., 2011; Gulumian, 2005; Hoidal, 2001). Free 
radicals generated from asbestos fibers plus the direct damage induced by the fibers are 
linked to cell signaling, inflammation, and a plethora of other responses (mutagenesis, 
proliferation, etc.) associated with the pathogenesis of asbestos-associated diseases (Heinz et 
al., 2010; Manning et al., 2002; Shukla et al., 2003a, 2003b). 
Several evidences indicate that a main factor in determining the surface and biological 
reactivity of different types of asbestos fibers is their ability to participate in redox reactions 
that generate free radicals (Kamp & Weitzman, 1999; Shukla et al., 2003a). Although the 
nature of the free radical-generating surface sites on asbestos fibers is not yet clear, asbestos 
fibers have an intrinsic redox activity and contain ferrous iron, which catalyzes reactions 
generating active oxygen intermediates on the fiber surface. Within the tissues several 
asbestos fiber types can produce reactive oxygen free radicals from hydrogen peroxide, a 
common product of intermediary tissue metabolism. Epidemiological studies have 
identified crocidolite as one of the most potent forms of asbestos associated with the 
induction of MM (Heintz et al., 2010). Crocidolite has a greater surface-area and a higher 
ferrous iron content compared to other fiber types such as chrysotile, and it is more 
biologically active in the generation of free radicals (Toyokuni, 2009). However, the ability of 
asbestos fibers to elicit these effects is not related to total iron content, suggesting the 
presence of specific iron active sites at the fibers’ surface (Shukla et al., 2003a).  
Cells exposed to asbestos have also been reported to produce a higher amount of nitric 
oxide (NO). In this regard, it has been reported that in human mesothelial cells crocidolite 
increases the expression of the inducible NO synthase (NOS) isoform (iNOS), the activity of 
the constitutive endothelial NOS (eNOS), and the synthesis of NO via NF-κB and Akt 
activation (Riganti et al., 2007). Thus, the asbestos-induced upregulation of iNOS or NO in 
the lungs, as well as the induction of inflammation by fibers, may contribute along with 
ROS, to the pathogenesis of lung and pleural injury (Hussain et al., 2003; Tanaka et al., 
1998). Indeed, ROS and RNS can cause breakage of DNA, lipid peroxidation, release of 
inflammatory cytokines such as TNF-α, and the modification of cellular proteins including 
phosphatases involved in cell signaling cascades (Gossart et al., 1996; Hussain et al., 2003), 
so that their increased synthesis by various cell types may have multiple roles in cellular 
events critical to the establishment of lung and pleural inflammation and uncontrolled cell 
proliferation. 
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Finally, in mesothelial and lung epithelial cells asbestos fibers, as opposed to nonpathogenic 
minerals, cause a persistent induction of the redox-sensitive transcription factors NF-κB and 
Activator Protein-1 (AP-1), which  is accompanied by chronic alterations in gene expression 
(Heintz et al., 1993; Janssen et al., 1995). As mentioned above, the aberrant activation of the 
NF-κB pathway is regarded as a critical event for mesothelial cell transformation (Toyooka 
et al., 2008). 
2.3. Transcription factors  
2.3.1. NF-κB 
NF-κB proteins are dimeric transcription factors composed of five different subunits, 
namely p65 (RelA), RelB, c-Rel, NF-κB1 p50 and NF-κB2 p52, which regulate gene 
expression events that impact on cell survival and differentiation. Moreover, since activation 
of NF-κB is critical in up-regulating the expression of many genes linked to proliferation, 
apoptosis resistance, and chemokine/cytokine production, this is undoubtedly a critical 
transcription factor in inflammatory responses occurring in target cells of asbestos-related 
diseases (Janssen et al., 1995, 1997). 
In unstimulated cells, the NF-κB transcription dimers are retained in the cytoplasm in an 
inactive state through the interaction with a family of inhibitors called IκBs (Inhibitors of κB) 
or with the p50 and p52 precursor proteins, p105 and p100, respectively (Hayden & Ghosh,  
2008; Scheidereit, 2006). Indeed, p50 and p52 are translated as precursors proteins 
containing an IκB-like C-terminal portion (Sun, 2011). 
Two different NF-κB-activation pathways exist: the classical and the alternative NF-κB 
pathway. The classical NF-κB pathway is initiated by signals elicited by diverse receptors, 
including TNF receptors type 1/2, Toll/IL-1 receptor, T-cell and B-cell receptors and EGF 
receptor, and also by cellular stresses and DNA damage (Hayden & Ghosh 2004; Le Page et 
al., 2005). These signals induce the activation of the IκB kinase (IKK) complex, which is 
composed by the catalytic subunits IKKα and IKKβ and by the regulatory subunit 
IKKγ/NEMO (Hayden & Ghosh, 2008; Scheidereit, 2006; Sun, 2011). The activated IKK 
complex phosphorylates IκB proteins, thereby triggering their proteasomal degradation. As 
a consequence, NF-κB dimers are released and can translocate into the nucleus. This 
pathway mainly leads to the activation of p50:RelA dimers (Sun, 2011). Conversely, the 
alternative NF-κB pathway predominantly targets activation of RelB:p52 complexes. This 
pathway relies on the inducible processing of p100 triggered by signaling from TNF 
receptor family members via the NF-κB-inducing kinase (NIK): NIK activates IKKα, which, 
in turn, phosphorylates p100 and triggers its processing to p52. This event results in the 
conversion of p100-inhibited NF-κB complexes into p52-containing NF-κB dimers, capable 
of translocating into the nucleus (Hayden & Ghosh, 2008; Scheidereit, 2006; Sun, 2011). 
NF-κB-regulated genes have distinct requirements for NF-κB dimers. For instance, the NF-
κB binding site of the IL-2 gene has been reported to bind preferentially c-Rel homodimers 
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and p50:c-Rel, while that of the gene encoding IL-8 has been found to selectively bind Rel A 
(Hoffman et al., 2003, 2006). On the other hand, several genes are redundantly induced by 
more than one dimer (Hoffman et al., 2003, 2006; Saccani et al., 2003). 
A number of studies have shown that nuclear retention and DNA binding of NF-κB protein 
complexes are increased following exposure of various cell types to a variety of extracellular 
stimuli that include oxidative stress (Bowie & O'Neill, 2000), hypoxia (Jung et al., 2003; 
Royds et al., 1998) and inflammatory cytokines (Mantovani et al., 2008). These observations 
are consistent with the hypothesis that persistent activation of NF-κB can contribute to the 
induction of multiple genes that are critical to the pathogenesis of asbestos-associated 
diseases, since oxidants, local hypoxia and inflammatory cytokines are all components 
involved in the effects induced by asbestos exposure. 
It is noteworthy that among various carcinogenic and non-carcinogenic fibers studied for 
their effect on nuclear translocation of NF-κB, only carcinogenic fibers were found to cause a 
dose-dependent translocation of this transcription factor to the nucleus, and this effect was 
reported to be oxidative stress-dependent (Brown et al., 1999). In lung macrophages, the 
asbestos-induced expression and secretion of TNF-α are mediated by iron-catalyzed ROS 
products (Simeonova & Luster, 1995) through a process that involves NF-κB activation (Cheng 
et al., 1999). In rat alveolar type 2 cells, the crocidolite-induced activation of NF-κB as well as 
the expression of the macrophage inflammatory protein-2 (MIP-2) gene have also been shown 
to be dependent on mitochondrial-derived oxidative stress (Driscoll et al., 1998).  
2.3.2. AP-1 
AP-1 is a homo- or heterodimeric transcription factor composed by proteins encoded by the 
fos and jun early response proto-oncogenes. This family of proteins includes c-Fos, FosB, 
FosL1 (Fra-1), FosL2 (Fra-2), c-Jun, JunB and JunD (Milde-Langosch, 2005). Whereas Jun 
members are capable of forming homodimers able to bind DNA and regulate transcription, 
all Fos members must form heterodimers with Jun family members to bind DNA.  
AP-1 is a redox-sensitive transcription factor typically associated with cell proliferation and 
tumor promotion (Eferl & Wagner, 2003). The first evidence showing that asbestos exerts 
regulatory effects linked to aberrant transcriptional responses, cell proliferation and cell 
transformation derives from studies in which asbestos fibers caused induction of c-fos and c-
jun proto-oncogene mRNAs in pleural mesothelial cells and tracheo-bronchial epithelial 
cells in a dose–response fashion (Heintz et al., 1993).  
The persistent induction of AP-1 by asbestos suggests a model of asbestos-induced 
carcinogenesis involving chronic stimulation of cell proliferation through activation of early 
response genes (Schonthaler et al., 2011). Of note, early response genes are a set of genes 
whose transcription is rapidly induced in response to growth factors. Furthermore, AP-1 
activity is induced by growth factors, pro-inflammatory cytokines and genotoxic stress 
(Jochum et al., 2001; Shaulian & Karin, 2002). These stimuli activate mitogen-activated 
protein kinase (MAPK) cascades through the phosphorylation of distinct substrates such as 
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ERK, JNK and p38 MAPK (Chang & Karin, 2001). Indeed, the MAPK signal transduction 
pathway uses AP-1 as a converging point not only to regulate the expression of various 
genes but also to autoregulate AP-1 gene transcription (Reuter et al., 2010).  
Several genes, which play very important roles in injury, repair, and differentiation, contain 
binding site(s) for AP-1 in their promoter and/or enhancer regions (Chang & Karin, 2001). 
These genes include extracellular matrix metalloproteinases (MMPs), antioxidant enzymes, 
growth factors and their receptors, differentiation markers, cytokines, chemokines and other 
transcription factors (Shaulian & Karin, 2001). 
2.3.3. Nuclear Factor of Activated T Cells (NFAT) 
The Nuclear Factor of Activated T cells (NFAT) family of transcription factors consists of 
five proteins that are evolutionarily related to the Rel/NF-κB family. NFAT can be present in 
both the cytoplasm and the nucleus. In the cytoplasm NFAT is in a highly phosphorylated, 
inactive state. Cell stimuli leading to the elevation of intracellular Ca2+ levels induce the 
activation of the phosphatase PP2B/Calcineurin which dephosphorylates NFAT. This results 
in its nuclear relocalization and transcriptional activation. Interestingly, NFAT family 
members can act synergistically with AP-1 on composite DNA elements which contain 
adjacent NFAT and AP-1 binding sites (Macián et al., 2001). A functional cooperation has 
also been reported to occur between NFAT and NF-κB (Jash et al., 2012). 
Initially, NFAT was identified in lymphocytes and was reported to be expressed in activated 
but not resting T cells (Macián et al., 2005; Shaw et al., 1988). NFAT regulates not only T cell 
activation and differentiation but also the function of other immune cells, including 
dendritic cells (DCs), B cells and megakaryocytes. In addition, NFAT has crucial roles in 
numerous developmental programs in vertebrates.  
Dysregulation of NFAT signalling is now known to be associated with malignant 
transformation and the development of cancer (Mancini & Toker, 2009; Müller & Rao, 2010). 
The observation that NFAT can be activated by asbestos-induced oxidative stress suggests 
that this transcription factor may play multiple roles in asbestos-induced inflammation and 
carcinogenesis (Li et al., 2002). Indeed, NFAT mediates the expression of several 
inflammatory cytokines, including TNF-α, and is involved in cell transformation, 
proliferation, invasive migration, tumor cell survival and tumor angiogenesis (Mancini & 
Toker, 2009).   
3. Multifaceted role of angiogenic growth factors in MM  
Angiogenesis is a common feature of solid tumors. Indeed, the development of a clinically 
observable tumor requires the neoformation of a vascular network sufficient to sustain 
tumor growth (Ribatti et al., 2007). Tumor angiogenesis is stimulated by the secretion of 
angiogenic molecules which induce endothelial cells from nearby vessels to switch from a 
quiescent to an activated state. Further, upon the stimulation of angiogenic growth factors, 
activated endothelial cells disrupt the extracellular matrix, proliferate and migrate (Ribatti et 
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al., 2007). Angiogenic growth factors include, among the others, Vascular Endothelial 
Growth Factor (VEGF), Placenta Growth Factor (PlGF), Platelet-Derived Growth Factor 
(PDGF) and acidic and basic Fibroblast Growth Factors (FGF-1 and -2, respectively). VEGF 
is regarded as the most important player in angiogenesis (Ono, 2008).  
The link between angiogenesis and tumor progression is provided by the negative prognostic 
value of intratumoral microvascular density (IMD) (Folkman, 2006;  Kerbel, 2008). In MM the 
IMD has an independent prognostic value (Kumar-Singh et al., 1997). MM demonstrates a 
higher IMD than colon and breast tumors and, consistently, presents with minimal central 
necrosis despite its huge size (Gasparini & Harris, 1995; Kumar-Singh et al., 1997). 
On the other hand, the involvement of angiogenic growth factors in MM goes beyond the 
stimulation of angiogenesis. Indeed, as discussed below, MM cells express receptors for 
several angiogenic factors which, accordingly, can directly modulate MM cell behavior.  
3.1. Angiogenic growth factors of the VEGF family 
The human VEGF family consists of five members: VEGF (VEGF-A), VEGF-B, VEGF-C, 
VEGF-D and PlGF. These growth factors are secreted as dimers and their biological effects 
are mediated by binding to three tyrosine kinase receptors, i.e. VEGF-R1/Flt-1, VEGF-
R2/KDR (whose murine homologue is known as Flk-1) and VEGF-R3/Flt-4, and two non-
enzymatic co-receptors known as neuropilin-1 and -2 (Ferrara et al., 2003; Koch et al., 2011; 
Roskoski, 2007).  
3.1.1. VEGF  
VEGF is regarded as the major mediator of tumor angiogenesis. It is expressed in the 
majority of cancers and has a central role in tumor growth and metastasis. In fact, this 
growth factor is essential for the mobilization of bone-marrow-derived endothelial 
precursors in neovascularization (Asahara et al., 1999), and stimulates vascular endothelial 
cells mobility, proliferation and survival (Waltenberger et al., 1994).  
High levels of VEGF are present both in malignant and non-malignant pleural effusions 
leading to increased vascular permeability. On the other hand, VEGF levels in serum or 
pleural effusions of MM patients are higher than those found in patients with non-
malignant pleuritis or lung cancer involving malignant pleural effusions. Further, in MM 
patients elevated serum or pleural effusion levels of VEGF correlate with a worse prognosis 
and may also contribute to increase resistance to chemotherapy (Hirayama et al., 2011; 
Yasumitsu et al., 2010; Zebrowski et al., 1999). In fact, VEGF status has proved to be of value 
in predicting the effectiveness of radiotherapy and chemotherapy on different cancers (Choi 
et al., 2008; Kumar et al., 2009; Toi et al., 2001).  
In addition to its role in tumor vascularization, VEGF can directly affect the behavior of 
cancer cells in an autocrine or paracrine manner. Indeed, many tumor cell types express 
VEGF receptors. VEGF has been found to promote the growth of transformed cell lines in 
vitro (Masood et al., 2001) and to act as a survival factor for tumor cells by enhancing the 
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expression of the antiapoptotic factors bcl-2 (Harmey & Bouchier-Hayes, 2002) and survivin 
(Kanwar et al., 2011). In this context, MM cells have been shown to express high amounts of 
VEGF, VEGF receptors and co-receptors both in vitro and in vivo, and VEGF has been 
demonstrated to act as an autocrine growth factor for this tumor cell type (Albonici et al., 
2009; Ohta et al., 1999; Pompeo et al., 2009;  Strizzi et al., 2001a).  
VEGF-R1 participates in cell migration; it has an important role in monocyte chemotaxis and 
promotes recruitment of circulating endothelial precursor cells from bone marrow (Hattori 
et al., 2002). Its expression is increased in various tumors, correlates with disease 
progression and can predict poor prognosis, metastasis and recurrent disease in humans 
(Dawson et al., 2009; Fischer et al., 2008; Kerber et al., 2008). This receptor is also expressed 
by MM cells in vitro and in vivo, where it appears to mediate proliferative and cell survival 
responses (Albonici et al., 2009;  Strizzi et al., 2001a). 
VEGF-R2 is the main mediator of VEGF-stimulated endothelial cell migration, proliferation, 
survival and enhanced vascular permeability (Olsson et al., 2006; Shibuya, 2006). VEGF-R2 
expression is induced in conjunction with active angiogenesis, such as during the reparative 
process, and in pathological conditions associated with neovascularization, such as cancer 
(Plate et al., 1993). VEGF-R2 is overexpressed in MM cells and specimens, and VEGF-R2 
silencing by small intefering RNA has been shown to induce cell death in MM or 
immortalized mesotelial cells in vitro (Albonici et al., 2009; Catalano et al., 2009; Pompeo et 
al., 2009; Strizzi et al., 2001a). Interestingly, it has been reported that in MM cells this 
receptor can be activated also via the semaphorin-6D receptor Plexin-A1, triggering a 
prosurvival program that promotes anchorage-independent growth through a NF-κB-
dependent pathway (Catalano et al., 2009). Remarkably, the expression of plexin-A1 is 
induced by asbestos fibers and overexpression of plexin-A1 in non-malignant mesothelial 
cells inhibits cell death after asbestos exposure, thus suggesting a role for this receptor not 
only in MM promotion and progression but also in asbestos-induced mesothelial 
carcinogenesis (Catalano et al., 2009).  
In vitro studies have shown that transfection of normal mesothelial cells with SV40 Tag 
potently increases VEGF protein and mRNA levels (Cacciotti et al., 2002) as well as 
mesothelial cell proliferation (Catalano et al., 2002). These data indicate that VEGF 
regulation by SV40 transforming proteins can also represent a key event in MM onset and 
progression. 
3.1.2. PlGF 
PlGF, originally identified in the placenta during the early embryonic development (Khaliq 
et al., 1996; Maglione et al., 1991), is expressed in several other organs including the heart, 
lung, thyroid, skeletal muscle and adipose tissue (Persico et al., 1999) but not normal 
mesothelium (Albonici et al., 2009). 
Although the role exerted by PlGF in tumor growth is controversial yet, PlGF can stimulate 
vessel growth and maturation directly by affecting endothelial and mural cells, as well as 
indirectly by recruiting pro-angiogenic cell types (Barillari et al., 1998; Carmeliet, 2003). It 
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also promotes the recruitment and maturation of angiogenesis-competent myeloid 
progenitors to growing sprouts and collateral vessels (Hattori et al., 2002; Luttun et al., 2002; 
Rafii et al., 2003). Further, PlGF is able to protect endothelial cells from apoptosis, in a 
similar manner as VEGF, by inducing the expression of antiapoptotic genes such as survivin 
(Adini et al., 2002).  
Under pathological conditions, PlGF abundance is elevated in various cell types and tissues, 
including vascular endothelial cells, and many different tumor cells (Albonici et al., 2009; 
Cao et al., 1996; Fischer et al., 2007; Oura et al., 2003). PlGF expression is switched on in 
hyperplastic/reactive mesothelium and in MM cells (Albonici et al., 2009). Moreover, in MM 
as well as in different types of cancer, including melanoma, gastric, colorectal and breast 
carcinomas, PlGF plasma levels and intratumoral expression have been found to correlate 
with tumor stage, vascularity, recurrence, metastasis and survival (Chen et al., 2004; 
Marcellini et al., 2006; Parr et al. 2005; Pompeo et al.; 2009; Wei et al., 2005).  
In vitro studies have shown that administration of recombinant PlGF to MM cells triggers 
the activation of Akt but does not elicit a significant stimulation of cell growth. Conversely, 
the administration of PlGF-neutralizing antibodies causes a significant reduction of MM cell 
viability, demonstrating the PlGF acts as a survival factor for MM cells (Albonici et al., 2009). 
PlGF binds VEGF-R1 and the co-receptors neuropilin-1 and -2, but, unlike VEGF, it does not 
bind VEGF-R2. Accordingly, it can act independently of VEGF in cells which primarily 
express VEGF-R1 (Fischer et al., 2007). Worthy of note, even though VEGF and PlGF both 
bind VEGF-R1, PlGF was reported to stimulate the phosphorylation of specific VEGF-R1 
tyrosine residues and the expression of distinct downstream target genes as compared to 
VEGF (Autiero et al., 2003). On the other hand, PlGF can also sustain VEGF activity through 
different mechanisms involving both VEGF-R1 and VEGF-R2. One of these mechanisms 
relies on the formation of PlGF:VEGF heterodimers. Indeed, PlGF:VEGF heterodimers have 
been isolated from cells producing both factors and shown to bind VEGF-R1:VEGF-R2 
receptor complexes, thus inducing receptor cross-talk and activation of VEGF-R2, the major 
mediator of VEGF activities (Autiero et al., 2003; Cao et al., 1996). In addition, the activation 
of VEGF-R1 by PlGF homodimers may induce the intermolecular transphosphorylation and 
activation of VEGF-R2 (Carmeliet et al., 2001). 
It is noteworthy that in vivo anti-PlGF treatment was reported to inhibit tumor growth 
without affecting healthy vessels, thus reducing tumor infiltration by angiogenic 
macrophages and severe tumor hypoxia, and preventing the switch on of the angiogenic 
rescue program leading to the enhanced release different angiogenic factors responsible for 
resistance to VEGF receptors inhibitors (Fischer et al., 2007). 
3.2. PDGF 
PDGFs comprise a family of dimeric growth factors structurally and functionally related to 
VEGFs  (Andrae et al., 2008). PDGF homodimers are formed by four different chains, i.e. 
PDGF-A, PDGF-B, PDGF-C and PDGF-D. In addition, PDGF-A and –B chains can form the 
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heterodimeric PDGF-AB. The biological effects of PDGF are mediated by two tyrosine 
kinase receptors, namely the PDGF receptor alpha (PDGFRα), which binds PDGF-A, -B, and 
–C chains, and the PDGF receptor beta (PDGFR), which binds PDGF-B and –D. Accordingly, 
upon ligand binding different receptor dimers may form depending on ligand configuration 
and the pattern of receptor expression. Cellular responses to PDGF signaling include 
stimulation of cell growth, differentiation, migration and inhibition of apoptosis (Andrae et 
al., 2008).  
An increased PDGF activity has been linked with tumors, vascular and fibrotic diseases 
(Andrae et al., 2008). Autocrine PDGF signaling leading to enhanced proliferation of tumor 
cells occurs in several types of cancer (Ostman, 2004). In addition, PDGF secretion by cancer 
cells and activated endothelial cells promotes the formation of both fibrous and vascular 
tumor stroma. In particular, PDGF-BB participates in tumor angiogenesis by stimulating 
endothelial cell motility and pericyte recruitment to neoformed vessels, thus leading to 
vessel stabilization, tumor cell survival and growth. Instead, both PDGF-AA and PDGF-BB 
appear involved in tumor recruitment of PDGFR-positive fibroblasts which, in turn, can be 
activated by PDGFs to produce VEGF and other tumor-promoting growth factors (Andrae 
et al., 2008; Cao et al., 2008; Homsi & Daud, 2007).  
Either high PDGF-AB serum levels or a strong expression of PDGFR signaling effectors in 
MM tissues have been associated with a lower survival in MM patients (Filiberti et al., 2005; 
Kothmaier et al., 2008). In fact, several evidence support a role for PDGF in MM promotion 
and progression through both autocrine and paracrine mechanisms.  
While PDGFRα expression levels are lower in MM than in normal mesothelial cells, 
PDGFRβ, PDGF-A and PDGF-B are overexpressed in MM cells as compared to their non-
transformed counterparts (Langerak et al., 1996a, 1996b; Metheny-Barlow et al., 2001). 
Functional studies have shown that transduction of MM cells with a hammerhead ribozyme 
against PDGFRβ mRNA reduced both PDGFRβ expression and MM cell proliferation, 
demonstrating the involvement of a PDGF-BB autocrine loop in MM cell growth (Dorai et al., 
1994). Conversely, the role of PDGF-A in MM cell proliferation is controversial. Indeed, the 
transfection of MM cells with antisense oligonucleotides to PDGF-A has been reported to 
either inhibit or stimulate MM cell growth in vitro (Garlepp & Leong, 1995; Metheny-Barlow et 
al., 2001). On the other hand, PDGF-A appears to play an important role in sustaining MM cell 
growth in vivo through paracrine mechanisms. Indeed, PDGF-A overexpression in MM cells 
inoculated in nude mice was found to increase tumor incidence, tumor growth rate and to 
decrease the latency period to tumor formation (Metheny-Barlow et al., 2001). In this regard, it 
has been suggested that PDGF-A participates in a malignant cytokine network through which 
MM cells instigates tumor-associated fibroblasts to produce growth factors, such as hepatocyte 
growth factor (HGF), with tumor-promoting activities (Li et al., 2011).  
3.3. FGF 
The FGF family encompasses 22 structurally related ligands in mammals. The effects of 
most FGF family members, including FGF-1 and -2, are mediated by binding to a family of 
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tyrosine kinase receptors designated FGF receptors (FGFR1 to FGFR5), whereas a smaller 
number of FGF isoforms does not bind FGFRs but interacts with voltage-gated sodium 
channels (Knights & Cook, 2010). 
FGFs regulate cell proliferation, differentiation, survival, wound healing and angiogenesis. 
In cancer, FGF signaling  is frequently de-regulated, resulting in mitogenic, anti-apoptotic 
and angiogenic responses (Knights & Cook, 2010). FGF-1 and -2, but also other less-studied 
FGF isoforms, exert pro-angiogenic effects by modulating proliferation and migration of 
endothelial cells and by stimulating the production of proteases (Lieu et al., 2011; Saylor et 
al., 2012). Worthy of note, it has been demonstrated that FGF-2 can synergize with both 
VEGF and PDGF-BB in stimulating neovascularization, this synergism relying on multiple 
mechanisms. For instance, FGF-2 promotes hypoxia-induced VEGF release by cancer cells 
and the expression of both VEGF and VEGFRs in endothelial cells, whereas VEGF, in turn, 
upregulates the expression of FGF-2 (Lieu et al., 2011; Saylor et al., 2012). Moreover, FGF-2 
upregulates PDGFRs expression and increases the responsiveness to PDGF-BB in 
endothelial cells, whereas PDGF-BB enhances FGFR1 expression and FGF-2 responsiveness 
in vascular smooth muscle cells (Cao et al., 2008; Liu et al., 2011). Remarkably, FGFs are 
thought to play a critical role in the resistance to anti-VEGF therapy (Lieu et al., 2011; Saylor 
et al, 2005). Besides, both FGF-1 and -2 may also be involved in tumor cell growth through 
cell-autonomous, autocrine mechanisms (Kumar-Singh et al., 1999).  
FGF-1 and -2 are expressed in the majority of MMs in vivo and high levels of FGF-2 in tumor 
tissues, serum or pleural effusions are associated with a worse prognosis in MM patients 
(Davidson et al., 2004; Kumar-Singh et al., 1999; Strizzi et al., 2001b). Furthermore, the 
combined expression levels of FGF-1, FGF-2, VEGF and Transforming Growth Factor beta 
(TGFβ) in MM tissues correlates with both IMD and a poorer prognosis (Kumar-Singh et al., 
1999). In addition to their role in tumor angiogenesis, FGFs act as autocrine growth factors 
for MM cells. Indeed, MM cells express FGFs and FGF receptors and the transfection with 
short interfering RNAs to FGF-1 and FGF-2 reduces MM cell proliferation (Kumar-Singh et 
al., 1999; Liu & Klominek, 2003; Stapelberg et al., 2005). It has also been reported that 
treatment of MM cells with exogenous FGF-2 stimulates the secretion of matrix 
metalloproteinases involved in tumor invasion and angiogenesis (Liu & Klominek, 2003). 
4. Cross-talk between inflammation and angiogenic growth factors  
Experimental and epidemiological evidences indicate that chronic inflammation is 
associated with most, if not all, tumors and supports their progression (Coussens & Werb 
2002; Mantovani et al., 2008; Mantovani et al., 2010; Porta et al., 2009). Chronic inflammation 
appears to have a versatile function in tumor onset and progression. Indeed, as discussed 
above, a long-lasting inflammation can contribute to cancer initiation through the 
production ROS and RNS with DNA-damaging properties. On the other hand, it can also 
participate in cancer promotion and progression by increasing the availability of mediators 
(growth factors, cytokines, chemokines, prostaglandins) which contribute to the growth of 
initiated cells and to neoangiogenesis (Mantovani, 2010). Besides, once a tumor is 
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established, cancer cells promote a constant influx of myelomonocytic cells that express 
inflammatory mediators supporting pro-tumoral functions. In this regard, myelomonocytic 
cells are key orchestrators of cancer-related inflammatory processes supporting proliferation 
and survival of malignant cells, subversion of adaptive immune responses, stromal 
remodeling and angiogenesis (David Dong et al., 2009; Loges et al., 2009; Porta et al., 2009).  
Tissue infiltration by macrophages is a dramatic and common feature of inflammation, 
angiogenesis and cancer (Pollard, 2004; Sica, 2010). High densities of tumor-infiltrating 
macrophages are associated with poor survival in patients with MM (Burt et al., 2011). In 
fact, the recruitment and infiltration of macrophages in the tumor microenvironment can 
activate them to support the malignant progression of cancer cells. These macrophages are 
called tumor-associated macrophages (TAMs) (Lawrence, 2011; Sica, 2010). Cancer cells co-
cultured with macrophages and incubated with inflammatory cytokines are synergistically 
stimulated to produce various angiogenesis-related factors (Izzi et al., 2009; Ono, 2008). This 
inflammatory angiogenesis is mediated, in part, by activation of NF-κB and AP-1 (Angelo & 
Kurzrock, 2007; Huang et al., 2000; Ono, 2008). In fact, treatment of both vascular 
endothelial cells and cancer cells with IL-1α/β, TNF-α and ROS in vitro results in a marked 
induction of VEGF and FGF-2, through the transcriptional activation of NF-κB, Specificity 
protein 1 (Sp-1), AP-1 and hypoxia response elements.  
In addition to macrophages, other tumor-infiltrating immune cells including T cells, B cells, 
natural killer cells and neutrophils can release cytokines, such as IL-1α/β, TNF-α and IL-6, 
able to sustain the synthesis of angiogenic growth factors (Angelo & Kurzrock, 2007). As for, 
IL-6, this pro-inflammatory cytokine has been reported to play a critical role in the 
stimulation of VEGF synthesis by different cell types, including MM cells (Adachi et al., 
2006; Angelo & Kurzrock, 2007). Of note, MMs usually produce high levels of IL-6 but 
express low levels of IL-6R, so that the presence of sIL-6Rs, which may be provided by 
inflammatory cells recruited to the tumor region, is essential for the IL-6-dependent 
stimulation of VEGF expression by MM cells (Adachi et al., 2006). Inflammation can also 
induce the expression of receptors for angiogenic growth factors. In this regard, the 
expression of PDGFRs is known to be induced by inflammatory cytokines such as TNF-α 
and IL-1 (Andrae et al.,  2008). Besides, inflammatory cells themselves can directly release 
angiogenic factors such as VEGF, PlGF, FGF-2 and PDGF, among many others, which exert 
mitogenic and migratory effects on surrounding cells (Sica 2010, Ono 2008). Inflammatory 
cells recruited in the tumor microenvironment can also produce matrix metalloproteinases 
which promote the formation of new vessels by degrading the basement membrane and by 
releasing angiogenic growth factors, such as VEGF, PlGF-2 and FGF-2, stored in the 
extracellular matrix (Barillari et al.,1998; Cao et al., 2008; Lieu et al., 2011). 
The high amount of chemokines/cytokines, growth factors, proteolytic enzymes, 
proteoglycans, lipid mediators and prostaglandins which is typically found in the tumor 
microenvironment sustains and exacerbates both inflammation and angiogenesis (Costa et 
al., 2007; Lin & Karin, 2007; Ono, 2008). In this context, the cross-talk between inflammation 
and angiogenesis is further corroborated by the evidence that, if on one hand inflammatory 
mediators have significant effects on angiogenesis, on the other hand angiogenic factors can 
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effectively promote inflammation. As a matter of fact, in addition to their angiogenic role, 
VEGF and PlGF appear to act as direct proinflammatory mediators in the pathogenesis of 
different inflammatory conditions (Angelo & Kurzrock, 2007; Yoo et al., 2008). In this 
regard, VEGF was found to increase the production of TNF-α and IL-6 by human peripheral 
blood mononuclear cells and macrophages (Yoo et al., 2008). Moreover, VEGF stimulates 
monocyte recruitment to tumor areas (Barleon et al., 1996). An additional link between 
inflammatory and angiogenic growth factors has been provided with the demonstration that 
in myelomonocytic cells TNF-α is upregulated by PlGF in a NFAT1-dependent manner and, 
in turn, contributes to PlGF-induced myelomonocytic cell recruitment (Ding et al., 2010). 
PlGF can also contribute to inflammation by acting as survival factor for monocytes and 
macrophages (Adini et al., 2002). 
5. Cooperation between asbestos and angiogenic growth factors in MM 
onset and progression 
As reported above, asbestos stimulates the expression of c-fos and c-jun mRNA in 
mesothelial cells in a dose-dependent fashion (Heintz et al., 1993; Ramos-Nino et al., 2002). 
One of the mechanisms by which VEGF and PlGF elicit biological responses is the induction 
of Fos-B and c-Fos expression in endothelial cells and monocytes (Holmes & Zachary, 2004). 
The coexistence of different stimuli, such as asbestos fibers and angiogenic growth factors, 
concurring to the activation of early response genes might lead to the persistent induction of 
AP-1 in mesothelial cells and to the chronic stimulation of mesothelial cell proliferation, thus 
favoring cell transformation.  
Further, asbestos and angiogenic growth factors can cooperate in inducing an 
immunosuppressive tumor microenvironement. Indeed, asbestos has been found to possess 
immunosuppressive properties. For example, chrysotile fibers have been shown to depress 
the in vitro proliferation of phytohemagglutinin-stimulated peripheral blood lymphocytes 
and to suppress natural killer activity. Moreover, asbestos significantly reduces the 
generation and activity of lymphokine-activated killer (LAK) cells, which are immune 
effectors with a strong lytic activity against MM cells (Manning et al., 1991; Valle et al., 
1998).  
Immunosuppressive properties have been reported for angiogenic growth factors as well 
(Ohm et al., 2001; Ziogas et al., 2012). Impaired antigen-presenting function in DCs as a 
result of abnormal differentiation is an important mechanism of tumor escape from immune 
control. It has been demonstrated that VEGF can inhibit the maturation of DCs induced by 
lipopolysaccharide (Takahashi et al., 2004). VEGF can also affect the ability of hematopoetic 
progenitor cells (HPCs) to differentiate into functional DCs during the early stages of 
hematopoiesis in vivo (Gabrilovich et al., 1996; Oyama et al., 1998). In this regard, it has been 
shown that VEGF binds to specific receptors on the surface of HPCs and this binding 
appears to involve VEGF-R1. Interestingly, the number of binding sites available for VEGF 
decreased with DC maturation and correlated with decreased levels of VEGF-R1 mRNA 
expression in the late-stage cells (Gabrilovich et al., 1996). PlGF was also found to inhibit the 
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activation and maturation of human DCs effectively and rapidly through the NF-κB 
pathway (Lin et al., 2007). The results of this study further indicate that by modulating the 
function of DCs, PlGF can down-regulate T helper immune responses (Lin et al., 2007). In 
addition, both VEGF and PlGF are also involved in the recruitment of macrophages with 
immunosuppressive, tumor-promoting roles to the tumor stroma.  
On the whole, these findings suggest mechanisms by which tumor-derived soluble factors 
such as VEGF or PlGF may synergize with asbestos to down-regulate immune responses to 
MM antigens.  
6. Conclusions 
Collectively, the reported findings demonstrate that a complex network involving asbestos, 
inflammation and angiogenic factors upregulation is involved in the pathogenesis of MM. In 
particular, the abnormal expression of angiogenic factors appears to play multiple roles in 
MM: it stimulates tumor neovascularization, increases pleural effusion formation by 
increasing vascular permeability, supports autocrine tumor cell growth and finally, in 
synergism with asbestos fibers, can sustain inflammation and bias host immune responses. 
Accordingly, the upregulation of angiogenic growth factors appears to be a crucial event in 
mesothelial cell transformation and MM progression. 
Given the involvement of multiple angiogenic growth growth factors in the formation of 
tumor vessels, in tumor inflammation and MM cell growth and survival, the therapeutic 
development of antiangiogenic agents for the treatment of this tumor should be aimed at 
blocking multiple growth factor signaling pathways and their complex interactive network 
(Cao et al., 2008; Ikuta et al., 2009; Homsi & Daud, 2007; Lieu et al., 2011). 
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